Dexrazoxane vs no cardioprotective intervention or placebo: Progression‐free survival
Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Dexrazoxane vs no cardioprotective intervention or placebo Progression‐free survival Defined as time from first date of complete response, partial response or stable disease until the date progressive disease was first noticed (Illustrative comparative risks reported as number of participants without prog... · adults with cancer receiving anthracyclines Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane Headline outcomes only | HR 0.62 [0.43, 0.9] | 1 study · 164 participants | Low |
Dexrazoxane vs no cardioprotective intervention or placebo Progression‐free survival Defined as time to progression; starting point nm (Illustrative comparative risks reported as number of participants without progression) · adults with cancer receiving anthracyclines Dexrazoxane showed no clear difference in progression‐free survival Defined as time to progression; starting… compared with no cardioprotective intervention or placebo (low certainty). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane Headline outcomes only | HR 0.95 [0.64, 1.4] | 1 study · 1 participants | Low |
Dexrazoxane vs no cardioprotective intervention or placebo Progression‐free survival Defined as time from randomisation to progression either on or off treatment (Illustrative comparative risks reported as number of participants without progression) · adults with cancer receiving anthracyclines Dexrazoxane showed no clear difference in progression‐free survival Defined as time from randomisation to… compared with no cardioprotective intervention or placebo (moderate certainty). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane Headline outcomes only | HR 1.18 [0.97, 1.43] | 2 studies · 2 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.